Ketamine for suicidality: An umbrella review

Summary

Ketamine shows preliminary evidence for short-term efficacy in reducing suicidal ideation, with most reviews supporting its benefits. Out of 27 studies, only four reported mixed or negative results, while five of nine reviews indicated significant benefits from esketamine. Common mild adverse effects included a rise in pulse rate and blood pressure, dissociation, confusion, blurred vision, nausea, and vertigo. However, many studies were of low quality, and long-term effects are still unknown.

Study at a glance

Abstract

The urgent need for appropriate treatment for suicide, the tenth leading cause of death, has led to numerous studies. This study aims to systematically identify and appraise systematic reviews with or without meta-analyses investigating ketamine in suicidal ideation and behaviours. Scopus, ISI, Embase, PubMed, CINAHL, PsycINFO, Cochrane Library, Google Scholar and two registries were searched without any restrictions for systematic reviews investigating the efficacy of ketamine on suicidal ideation and behaviours. The primary outcome was the final inference of ketamine effectiveness. A formal narrative synthesis was conducted, and the AMSTAR-2 tool was used to evaluate the quality of the studies. Of 27 studies that addressed ketamine for suicidal ideation, only four reported mixed or negative results, and out of nine reviews, esketamine was significantly beneficial only in five. A transient rise in pulse rate and blood pressure, dissociation, confusion, blurred vision, nausea and vertigo were the most common adverse effects; however, most were mild. More than two-thirds of the included studies qualified as of low or critically low quality. Preliminary evidence for the short-term efficacy of ketamine in suicidality was noted by the majority of reviews; however, long-term effects remained unknown. Due to the low quality of many studies and the limitations of core studies, further research is required.

Tags